Page 951 - Basic _ Clinical Pharmacology ( PDFDrive )

CHAPTER 52 Antiprotozoal Drugs 937

Bisser S et al: Equivalence trial of melarsoprol and nifurtimox monotherapy and Priotto G et al: Nifurtimox-eflornithine combination therapy for second-stage
combination therapy for the treatment of second-stage Trypanosoma brucei African Trypanosoma brucei gambiense trypanosomiasis: A multicentre, ran-
gambiense sleeping sickness. J Infect Dis 2007;195:322. domised, phase III, non-inferiority trial. Lancet 2009;374:56.
Brun R, Blum J: Human African trypanosomiasis. Infect Dis Clin North Am Rassi A Jr, Rassi A, Marcondes de Rezende J: American trypanosomiasis (Chagas
2012;26:261. disease). Infect Dis Clin North Am 2012;26:275.
Brun R et al: Human African trypanosomiasis. Lancet 2010;375:148. Rassi A et al: Chagas disease. Lancet 2010;375:1388.
Burza S et al: Five-year field results and long-term effectiveness of 20 mg/kg lipo- Rubiano LC et al: Noninferiority of miltefosine versus meglumine antimoniate for
somal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India. cutaneous leishmaniasis in children. J Infect Dis 2012;205:684.
PLoS Negl Trop Dis 2014;8:e2603. Sosa N et al: Randomized, double-blinded, phase 2 trial of WR 279,396 (paromo-
Goto H, Lauletta Lindoso JA: Cutaneous and mucocutaneous leishmaniasis. Infect mycin and gentamicin) for cutaneous leishmaniasis in Panama. Am J Trop
Dis Clin North Am 2012;26:293. Med Hyg 2013;89:557.
Hailu A et al: Geographical variation in the response of visceral leishmaniasis to Sundar S et al: Comparison of short-course multidrug treatment with standard
paromomycin in East Africa: A multicentre, open-label, randomized trial. therapy for visceral leishmaniasis in India: An open-label, non-inferiority,
PLoS Negl Trop Dis 2010;4:e709. randomised controlled trial. Lancet 2011;377:477.
Jackson Y et al: Tolerance and safety of nifurtimox in patients with chronic Chagas Sundar S et al: Efficacy of miltefosine in the treatment of visceral leishmaniasis in
disease. Clin Infect Dis 2010;51:e69. India after a decade of use. Clin Infect Dis 2012;55:543.
Kennedy PG: Clinical features, diagnosis, and treatment of human African try- Sundar S et al: Efficacy and safety of amphotericin B emulsion versus liposomal
panosomiasis (sleeping sickness). Lancet Neurol 2013;12:186. formulation in Indian patients with visceral leishmaniasis: a randomized,
Lescure FX et al: Chagas disease: Changes in knowledge and management. Lancet open-label study. PLoS Negl Trop Dis 2014;8:e3169.
Infect Dis 2010;10:556. Sundar S, Singh A: Recent developments and future prospects in the treatment of
Lutje V, Seixas J, Kennedy A: Chemotherapy for second-stage human African try- visceral leishmaniasis. Ther Adv Infect Dis 2016;3:98.
panosomiasis. Cochrane Database Syst Rev 2013;(6):CD006201. Sundar S et al: Single-dose liposomal amphotericin B for visceral leishmaniasis in
Morillo CA et al: Randomized trial of benznidazole for chronic Chagas’ cardiomy- India. N Engl J Med 2010;362:504.
opathy. N Engl J Med 2015;373:1295. van Griensven J, Diro E: Visceral leishmaniasis. Infect Dis Clin North Am
Murray HW: Leishmaniasis in the United States: Treatment in 2012. Am J Trop 2012;26:309.
Med Hyg 2012;86:434. van Griensven J et al: Combination therapy for visceral leishmaniasis. Lancet Infect
Murray HW et al: Advances in leishmaniasis. Lancet 2005;366:1561. Dis 2010;10:184.
Musa A et al: Sodium stibogluconate (SSG) & paromomycin combination Vélez I et al: Efficacy of miltefosine for the treatment of American cutaneous leish-
compared to SSG for visceral leishmaniasis in East Africa: A randomised maniasis. Am J Trop Med Hyg 2010;83:351.
controlled trial. PLoS Negl Trop Dis 2012;6:e1674.

C ASE STUD Y ANSWER

This child has acute falciparum malaria, and her lethargy closely for progression of severe malaria, in particular neu-
and abnormal laboratory tests are consistent with progres- rologic, renal, or pulmonary complications, and if treated
sion to severe disease. She should be hospitalized and treated with quinine or quinidine should have cardiac monitoring
urgently with intravenous artesunate or, if this is unavailable, for potential toxicities.
intravenous quinine or quinidine. She should be followed